120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
用于难治性实体瘤硼中子俘获治疗的靶向纳米硼递送平台
Authors Ma Z, Ma Z, Wang X, Li Y, Li L, Li L, Ji P , Yan Q
Received 14 November 2025
Accepted for publication 29 January 2026
Published 6 February 2026 Volume 2026:21 581215
DOI https://doi.org/10.2147/IJN.S581215
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Dong Wang
Zhenchao Ma,1,2,* Ziyan Ma,3,* Xinlin Wang,3 Yaru Li,3 Lian Li,3 Luzixuan Li,3 Peng Ji,3 Qiang Yan1
1Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang Province, 313000, People’s Republic of China; 2Boron Neutron Capture Cancer Treatment Technology, Zhejiang Engineering Research Center, Huzhou, Zhejiang Province, 313000, People’s Republic of China; 3School of Pharmacy, Taizhou University, Taizhou, Jiangsu Province, 225300, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Peng Ji, School of Pharmacy, Taizhou University, No. 93, Jichuan East Road, Taizhou, Jiangsu Province, 225300, People’s Republic of China, Email jipeng0213@163.com Qiang Yan, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, No. 1558 North Sanhuan Road, Huzhou, Zhejiang Province, 313000, People’s Republic of China, Email yianq@hzhospital.com
Abstract: Boron neutron capture therapy (BNCT) represents a promising binary radiotherapy for refractory solid tumors. However, its clinical translation has been historically constrained by the suboptimal pharmacokinetics of conventional boron agents (eg, BPA and BSH), characterized by low tumor selectivity and rapid clearance. This review provides a comprehensive analysis of how nanoengineered delivery platforms—including lipid-based, polymeric, inorganic, and biomimetic nanocarriers—are revolutionizing BNCT. We focus on their advanced targeting mechanisms (passive EPR effect, active ligand/receptor engagement, and nuclear localization), which collectively enable significantly enhanced tumor boron accumulation (T/N ratios of 6– 17) and prolonged intratumoral retention. Furthermore, we critically examine the integration of multimodal imaging techniques (PET, MRI) for real-time dosimetry and treatment planning, which is essential for precision-guided BNCT. Despite remarkable preclinical progress, key translational challenges persist, including the standardization of neutron sources, long-term biocompatibility of nanocarriers, and scalable GMP-compliant manufacturing. In conclusion, the convergence of targeted nanomedicine, precision imaging, and immunomodulation is forging a robust platform. This positions BNCT as an emerging, clinically viable modality within the precision oncology arsenal for refractory malignancies.
Keywords: nanodelivery system, boron neutron capture therapy, targeted controlled release, refractory tumors, boron carrier
1Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang Province, 313000, People’s Republic of China; 2Boron Neutron Capture Cancer Treatment Technology, Zhejiang Engineering Research Center, Huzhou, Zhejiang Province, 313000, People’s Republic of China; 3School of Pharmacy, Taizhou University, Taizhou, Jiangsu Province, 225300, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Peng Ji, School of Pharmacy, Taizhou University, No. 93, Jichuan East Road, Taizhou, Jiangsu Province, 225300, People’s Republic of China, Email jipeng0213@163.com Qiang Yan, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, No. 1558 North Sanhuan Road, Huzhou, Zhejiang Province, 313000, People’s Republic of China, Email yianq@hzhospital.com
Abstract: Boron neutron capture therapy (BNCT) represents a promising binary radiotherapy for refractory solid tumors. However, its clinical translation has been historically constrained by the suboptimal pharmacokinetics of conventional boron agents (eg, BPA and BSH), characterized by low tumor selectivity and rapid clearance. This review provides a comprehensive analysis of how nanoengineered delivery platforms—including lipid-based, polymeric, inorganic, and biomimetic nanocarriers—are revolutionizing BNCT. We focus on their advanced targeting mechanisms (passive EPR effect, active ligand/receptor engagement, and nuclear localization), which collectively enable significantly enhanced tumor boron accumulation (T/N ratios of 6– 17) and prolonged intratumoral retention. Furthermore, we critically examine the integration of multimodal imaging techniques (PET, MRI) for real-time dosimetry and treatment planning, which is essential for precision-guided BNCT. Despite remarkable preclinical progress, key translational challenges persist, including the standardization of neutron sources, long-term biocompatibility of nanocarriers, and scalable GMP-compliant manufacturing. In conclusion, the convergence of targeted nanomedicine, precision imaging, and immunomodulation is forging a robust platform. This positions BNCT as an emerging, clinically viable modality within the precision oncology arsenal for refractory malignancies.
Keywords: nanodelivery system, boron neutron capture therapy, targeted controlled release, refractory tumors, boron carrier